ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus

Systemic Lupus Erythematosus

Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus

J Am Coll Cardiol

Yafasova A, Fosbøl EL, Schou M, Baslund B, Faurschou M, Docherty KF, Jhund PS, McMurray JJV, Sun G, Kristensen SL, Torp-Pedersen C, Køber L, Butt JH

doi: 10.1016/j.jacc.2021.02.029

Systemic Lupus Erythematosus

Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis

Ann Rheum Dis.

Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, Frontini G, Alberici F, Sacchi L, Binda V, Trezzi B, Vaglio A, Messa P, Sinico RA, Doria A

doi: 10.1136/annrheumdis-2020-216965.

Systemic Lupus Erythematosus

Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus: an exploratory study

Rheumatology (Oxford).

Fasano S, Pierro L, Borgia A, Coscia MA, Formica R, Bucci L, Riccardi A, Ciccia F

doi: 10.1093/rheumatology/keaa074.

Systemic Lupus Erythematosus

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

J Rheumatol

Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW, Suh CH

doi: 10.3899/jrheum.200802

Systemic Lupus Erythematosus

Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program

Arthritis Care Res (Hoboken).

Charoenwoodhipong P, Harlow SD, Marder W, Hassett AL, McCune WJ, Gordon C, Helmick CG, Barbour KE, Wang L, Mancuso P, Somers EC, Zick SM

doi: 10.1002/acr.23925.

Juvenile Idiopathic Arthritis

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Ann Rheum Dis.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ

doi: 10.1136/annrheumdis-2018-213150.

Systemic Lupus Erythematosus

Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort

Rheumatology (Oxford).

Segura BT, Bernstein BS, McDonnell T, Wincup C, Ripoll V, Giles I, Isenberg D, Rahman A

doi: 10.1093/rheumatology/kez292.

Autoimmune DiseaseSystemic Lupus Erythematosus

Elevated Semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.

Clin Exp Immunol.

Du Y, Wu X, Chen M, Wang W, Xv W, Ye L, Wu D, Xue J, Sun W, Luo J, Wu H

doi: 10.1111/cei.12924.

Systemic Lupus Erythematosus

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

doi: 10.1136/annrheumdis-2018-214427.

Related content

Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus

Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis

Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus: an exploratory study

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort

Elevated Semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus